Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Cash from Investing Activities (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Cash from Investing Activities for 7 consecutive years, with $108.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Investing Activities fell 14.15% to $108.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$121.4 million, a 165.64% decrease, with the full-year FY2025 number at -$121.4 million, down 165.64% from a year prior.
  • Cash from Investing Activities was $108.4 million for Q4 2025 at Beam Therapeutics, up from $65.7 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $126.3 million in Q4 2024 to a low of -$537.3 million in Q1 2022.
  • A 5-year average of -$31.0 million and a median of -$5.7 million in 2022 define the central range for Cash from Investing Activities.
  • Peak YoY movement for Cash from Investing Activities: crashed 3186.85% in 2023, then surged 341.43% in 2024.
  • Beam Therapeutics' Cash from Investing Activities stood at -$77.5 million in 2021, then soared by 246.38% to $113.4 million in 2022, then fell by 13.52% to $98.1 million in 2023, then increased by 28.73% to $126.3 million in 2024, then dropped by 14.15% to $108.4 million in 2025.
  • Per Business Quant, the three most recent readings for BEAM's Cash from Investing Activities are $108.4 million (Q4 2025), $65.7 million (Q3 2025), and -$170.4 million (Q2 2025).